Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 July 2021 | Story André Damons | Photo Supplied
Mutshidzi Abigail Mulondo, Lecturer and PhD candidate in the Faculty of Health Sciences at the University of the Free State (UFS), has been recognised as one of the Mail & Guardian’s 200 Young South Africans.

For Mutshidzi Abigail Mulondo, Lecturer and PhD candidate in the Faculty of Health Sciences at the University of the Free State (UFS), being recognised as one of the Mail & Guardian 200 Young South Africans is encapsulated in Mark Twain’s quote, “The two most important days in your life are the day you are born and the day you find out why”.

Knowing that she is living her ‘why I was born’ and actually being recognised for it, is a wonderful feeling, says Mulondo, whose passion is public health.

“I feel honoured to have been considered and counted among influential young South Africans who are doing incredible work. I am thankful to Mail & Guardian for this wonderful recognition,” says Mulondo.

Passion and commitment to promoting health 

She was nominated by one of her mentors but was sceptical that she would be in the final 200 list, as there are usually more than 5 000 applications each year. According to Mulondo, she is happy to have been proven wrong and even more grateful to be surrounded by powerful women who continue to propel her towards her purpose.

Mulondo says she always knew that she wanted to be in a position to help alleviate pain and suffering and that health would be her avenue to serve humanity. Says Mulondo: “When I started with an interdisciplinary PhD in Health Professions Education and Community Health, it further solidified my passion and commitment to promoting health.”
“I am equally passionate about mental health wellness. After completing a master’s degree in Psychology at the University of Pretoria, I knew it would provide me with an opportunity to impact people’s lives more holistically. An opportunity to not only promote physical health, but to also advocate for mental health.”

Hope for the youth of South Africa

Mulondo’s message to young people is also the motto she lives by: “Be kinder to yourself”. So many times, we are hard on ourselves when we fail or when we do not accomplish what we set out to accomplish at a particular time. 

“Please remember that you are the only you that will ever be. You must therefore be gentler with yourself; despite what you thought you would have achieved thus far, appreciate how far you have actually come against whatever odds,” says Mulondo.

Her hope for the youth of South Africa is that we reach a point where fighting against issues such as gender-based violence (GBV), systematic racism, gender inequality, high unemployment rates, and all other constructs that affect our youth and country is a matter of the past. “While we envision that day, I hope that we all continue to stand together and speak up for the vulnerable, marginalised, and disenfranchised. I am confident that we will see and experience the fullest potential of our youth, in this lifetime (Jeremiah 29:11).”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept